Business context and reporting period
This is Homology Medicines, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018—not a filing by Q32 Bio Inc. Homology was a preclinical-stage genetic medicines company developing gene therapy and nuclease-free gene-editing programs for rare diseases. Its lead candidate, HMI-102, was being advanced for phenylketonuria (PKU); no human clinical trials had begun.
Financial performance and position
| Metric | Q2 2018 | Six months 2018 | Comparable 2017 period |
|---|---|---|---|
| Collaboration revenue | $0.9 million | $1.75 million | None |
| Research and development expense | $10.3 million | $18.3 million | $4.1 million / $6.9 million |
| General and administrative expense | $4.5 million | $8.4 million | $2.0 million / $3.9 million |
| Net loss | $12.9 million | $23.4 million | $6.0 million / $11.6 million |
| Net loss per share | $0.35 | $1.19 | $2.61 / $4.89 |
Revenue came from the Novartis collaboration; the company had no product sales and no meaningful positive operating margin. For the six months, operating cash use was $20.8 million. Investing cash use was $86.8 million, primarily reflecting purchases of short-term investments and property and equipment; financing provided $150.9 million, mainly from the IPO.
At June 30, cash and cash equivalents were $95.0 million and short-term investments were $160.5 million, totaling approximately $255.5 million. Current assets were $261.6 million, current liabilities $10.9 million, and total liabilities $43.5 million. The company reported no debt. Management said available cash, cash equivalents and short-term investments were expected to fund operations for at least two years, subject to assumptions and execution risks.
Material changes versus the prior comparable period
- Six-month operating expenses rose to $26.6 million from $10.7 million; net loss increased to $23.4 million from $11.6 million.
- R&D expense increased by $11.4 million, principally from HMI-102 external development and manufacturing costs, higher headcount, and other preclinical activity. G&A increased by $4.5 million, including employee and facility costs and public-company expenses.
- The April 2018 IPO raised $150.8 million net. Preferred shares converted into common stock at the IPO, and stockholders’ equity was $226.8 million at quarter-end, versus a deficit at year-end 2017.
- Interest income rose to $1.5 million for the first half, reflecting higher investment balances. The prior-year period included a $0.9 million expense from remeasurement of a preferred-stock tranche liability, which was no longer outstanding in 2018.
Outlook, risks and unusual items
- Management expected to initiate a Phase 1/2 HMI-102 trial in adults with PKU and obtain initial clinical data in 2019; it expected to nominate a lead gene-editing candidate for pediatric PKU in 2018. These were forward-looking plans, not completed milestones.
- The Novartis agreement covers ophthalmic targets and sickle cell disease. Homology recognized collaboration revenue over an estimated ten-year performance period; $33.2 million remained deferred at June 30. Potential contingent payments include up to $960 million in development, regulatory and commercial milestones, plus tiered royalties; these amounts were not guaranteed revenue.
- The company expected operating expenses and capital spending to rise as it advanced programs, built manufacturing capability and expanded facilities. It estimated $22–24 million of facility and equipment capital expenditures through the first half of 2019, net of an expected landlord allowance of approximately $10.8 million. Future minimum lease payments were $27.9 million.
- Key risks include preclinical and clinical failure, regulatory uncertainty for novel gene therapies and gene editing, manufacturing scale-up and supplier dependence, intellectual-property claims, and the need for future financing. The filing states that additional capital may be needed beyond the estimated two-year runway.
- The filing reported no material legal proceedings; management said disclosure controls were effective as of June 30, 2018.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Homology Medicines, Inc., not Q32 Bio Inc.
- Track whether HMI-102 entered the planned Phase 1/2 trial and whether timing or expected data milestones changed.
- Assess cash burn, capital expenditures, manufacturing build-out and whether management’s stated runway assumptions remain supportable.
- Review the Novartis agreement’s performance obligations, deferred revenue, target-selection progress and conditions attached to contingent milestones and royalties.
- Evaluate the impact of equity compensation, potential share sales after IPO lock-ups, and any future financing on dilution.